Kalmar Investments Inc. DE lowered its stake in shares of Core Laboratories NV (NYSE:CLB) by 23.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,445 shares of the company’s stock after selling 42,295 shares during the period. Kalmar Investments Inc. DE owned about 0.32% of Core Laboratories NV worth $17,524,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. BlackRock Institutional Trust Company N.A. raised its stake in shares of Core Laboratories NV by 0.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 724,290 shares of the company’s stock valued at $81,417,000 after buying an additional 3,461 shares during the period. State Street Corp raised its stake in shares of Core Laboratories NV by 1.6% in the first quarter. State Street Corp now owns 464,720 shares of the company’s stock valued at $52,230,000 after buying an additional 7,339 shares during the period. BlackRock Group LTD raised its stake in shares of Core Laboratories NV by 5.4% in the first quarter. BlackRock Group LTD now owns 280,960 shares of the company’s stock valued at $31,582,000 after buying an additional 14,434 shares during the period. Geode Capital Management LLC raised its stake in shares of Core Laboratories NV by 4.1% in the first quarter. Geode Capital Management LLC now owns 227,422 shares of the company’s stock valued at $25,549,000 after buying an additional 8,979 shares during the period. Finally, Mar Vista Investment Partners LLC raised its stake in shares of Core Laboratories NV by 0.6% in the second quarter. Mar Vista Investment Partners LLC now owns 197,120 shares of the company’s stock valued at $24,421,000 after buying an additional 1,117 shares during the period.

Institutional Ownership by Quarter for Core Laboratories NV (NYSE:CLB)

Shares of Core Laboratories NV (NYSE:CLB) traded up 3.28% during midday trading on Wednesday, reaching $115.10. 593,036 shares of the company’s stock traded hands. The stock has a market cap of $5.08 billion, a P/E ratio of 61.06 and a beta of 1.45. Core Laboratories NV has a 52-week low of $84.50 and a 52-week high of $135.49. The stock has a 50-day moving average price of $110.34 and a 200-day moving average price of $117.55.

Core Laboratories NV (NYSE:CLB) last posted its quarterly earnings results on Wednesday, October 19th. The company reported $0.38 earnings per share for the quarter, missing analysts’ consensus estimates of $0.39 by $0.01. Core Laboratories NV had a net margin of 11.81% and a return on equity of 344.55%. The company earned $143.50 million during the quarter, compared to analyst estimates of $155.72 million. During the same quarter in the previous year, the business posted $0.83 earnings per share. The company’s revenue for the quarter was down 27.3% on a year-over-year basis. Analysts forecast that Core Laboratories NV will post $1.54 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 22nd. Stockholders of record on Friday, October 21st will be paid a $0.55 dividend. The ex-dividend date of this dividend is Wednesday, October 19th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.91%. Core Laboratories NV’s payout ratio is currently 117.65%.

A number of equities analysts have commented on CLB shares. Zacks Investment Research upgraded shares of Core Laboratories NV from a “sell” rating to a “hold” rating in a research report on Thursday, October 6th. Citigroup Inc. reduced their price target on shares of Core Laboratories NV from $118.00 to $116.00 and set a “neutral” rating on the stock in a research report on Monday, September 12th. Credit Suisse Group AG started coverage on shares of Core Laboratories NV in a research report on Thursday, September 1st. They issued a “neutral” rating and a $115.00 price target on the stock. Loop Capital started coverage on shares of Core Laboratories NV in a research report on Friday, September 30th. They issued a “hold” rating and a $120.00 price target on the stock. Finally, JPMorgan Chase & Co. lowered shares of Core Laboratories NV from a “neutral” rating to an “underweight” rating in a research report on Tuesday, July 12th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $121.61.

Core Laboratories NV Company Profile

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

5 Day Chart for NYSE:CLB

Receive News & Stock Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related stocks with our FREE daily email newsletter.